Vardenafil hydrochloride Property

Melting point:

214-216°C

storage temp. 

Store at -20°C

solubility 

DMSO: 100 mg/mL (190.45 mM); Water: ≥ 100 mg/mL (190.45 mM)

form 

Solid

color 

White to Off-White Cyrstalline

InChI

InChI=1S/C23H32N6O4S.ClH/c1-5-8-20-24-16(4)21-23(30)25-22(26-29(20)21)18-15-17(9-10-19(18)33-7-3)34(31,32)28-13-11-27(6-2)12-14-28;/h9-10,15H,5-8,11-14H2,1-4H3,(H,25,26,30);1H

InChIKey

XCMULUAPJXCOHI-UHFFFAOYSA-N

SMILES

C(C1=NC(C)=C2C(N=C(C3C=C(S(N4CCN(CC)CC4)(=O)=O)C=CC=3OCC)NN12)=O)CC.Cl

Safety

HS Code 

2933299090

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Danger

Hazard statements

H301Toxic if swalloed

H311Toxic in contact with skin

H331Toxic if inhaled

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P271Use only outdoors or in a well-ventilated area.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P302+P352IF ON SKIN: wash with plenty of soap and water.

P304+P340IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.

P310Immediately call a POISON CENTER or doctor/physician.

P330Rinse mouth.

P361Remove/Take off immediately all contaminated clothing.

P403+P233Store in a well-ventilated place. Keep container tightly closed.

P405Store locked up.

P501Dispose of contents/container to..…

Vardenafil hydrochloride Chemical Properties,Usage,Production

Description

Vardenafil was the second agent to be marketed and had the advantage that its onset time was not reduced by taking the medication on a full stomach . It is 30 times more potent as an inhibitor of PDE5 (mean IC50, 3.9 nM) than sildenafil and 10 times more potent than tadalafil, with a greater selectivity (>1,000 times) for human PDE5 than for human PDE2, PDE3, and PDE4 and moderate selectivity (>80 times) for PDE1. The PDE inhibitory selectivity and both the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Vardenafil specifically inhibited the hydrolysis of cGMP by PDE5, with an IC50 of 0.7 nM (sildenafil 6.6 nM). The IC50 of vardenafil for PDE1 was 180 nM, for PDE6 11 nM, and for PDE2, PDE3 and PDE4 more than 1,000 nM.

Chemical Properties

White to Off-White Cyrstalline Solid

Uses

vardenafil hydrochloride is a selective phsphodiesterase type 5 (pde5) inhibitor that is used as a urological agent in the treatment of erectile dysfunction.

General Description

Vardenafil, 4-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonyl-phenyl]-9-methyl-7-propyl-3,5,6,8-tetrazabicyclo[4.3.0]nona-3,7,9-trien-2-one(Levitra), was the second PDE5 introduced in the U.S. market.The metabolism of vardenafil is primarily by CYP3A4.As such, concomitant use of CYP3A4 inhibitors such as ritonavir,indinavir, ketoconazole, as well as moderate CYP3Ainhibitors such as erythromycin typically results in significantincreases of plasma levels of vardenafil.

Synthesis

The synthesis started with 2- hydroxybenzonitrile. 2-Hydroxybenzonitrile (181) was alkylated with ethyl bromide to give 2-ethoxybenzonitrile in 97% yield as a liquid which was subsequently treated with AlMeClNH2, prepared from AlMe3 and NH4Cl, to give corresponding 2-ethoxybenzamidine (182) in 76% yield as a solid. Compound 182 was treated with hydrazine hydrate in ethanol to give hydrazide 183, which was used in the next step without isolation. Dakin-West reaction of 2- butyrylaminopropionic acid (184) with ethyl oxalyl chloride (185) in the presence of DMAP in refluxing pyridine/THF to give corresponding |á-oxoamino-acid ester 186 which was also used for next step without isolation. Hydrazide 183 was condensed with ester 186 in refluxing ethanol to give triazinone 187 intermediate which was then cyclized to the final core structure, imidazo[5,1-f]triazin-4-one, using POCl3 to give 188 in 28% yield from 183. Compound 188 was sulfonylated with chlorosulfonic acid to give sulfonyl chloride 189 in 91% yield. Finally, 189 was condensed with N-ethylpiperazine (190) in dichloromethane to give vardenafil (XXIII) in 66% yield.

in vitro

Vardenafil hydrochloride specifically inhibits the hydrolysis of cGMP by PDE5 with an IC50 of 0.7 nM. Vardenafil hydrochloride increases intracellular cGMP levels in the cavernosum tissue of the penis, thus results increasing the dilation of the body's sinuses and blood flow.

in vivo

Vardenafil hydrochloride (I.V.; 0.03 mg/kg) exhibits facilitator effects in rats with cavernous nerve injury.
Vardenafil hydrochloride (I.V.; 0.17 mg/kg once daily for 7 days) protects the liver against Con A-induced hepatitis and decreases the expression of NF--.
Vardenafil hydrochloride (P.O.; 10 mg/kg once daily; 25 weeks) prevents the reduction of tissue cGMP levels and the increase in 3-NT generation in ZDF hearts.

Enzyme inhibitor

Vardenafil also is rapidly absorbed and peaks in concentration (9.05 μg/mL after a 10-mg dose) after 0.9 hours, displaying a half-life of 4 to 5 hours. The absorption rate of both sildenafil and vardenafil are reduced when taken with a high-fat diet. The drug also is metabolized by hepatic CYP3A4, and a potential for drug–drug interaction with inhibitors or enhancers of CYP3A4 exists. Biochemical studies demonstrate a significant increase in selectivity of vardenafil over sildenafil for PDE5 versus PDE6. Whether this translates into a significant improvement in side effects must await studies in a greater population of patients.